Things have been way too quiet and the stock is getting crushed (my guess by impatient traders) since there has been a void of news. I have no contact with the company but I believe they are still waiting on FDA approval of the Phase 2b protocol, though I believe the CRO that they contracted with is ready to start when approval is given. Based on past press releases, I think the trial is scheduled to begin in the third quarter, so I hope we hear news from the FDA soon. While NTRP is as speculative as you can get, I think Bryostatin is one of the most promising AD drugs to be tested. You can read on the BRNI website about the 6 years of various testing they did and how the drug worked in multiple models to reduce AD proteins, amyloid plaque deposits, and restored memory. Gotta hold this for the long term.
Thanks everyone for all the good feedback. I have more research to do on AVXL. I don't short stocks. I am long only, and like to trade and invest in biotech stocks. I'm also looking into NTRP if you're interested in more AD stocks.
I recently reviewed their latest corporate presentation and I really liked what I saw and the potential of AVXL. But before I buy I did some more due diligence and I wanted to present what I think are huge red flags to see if I am off base.
AVXL continues to publish misleading press releases stating they are “Reporting New Data” about Sigma-1 Receptor functionality when in fact the studies being referred to in these releases were not in any way related to testing of their drug and there was no direct involvement by AVXL in any of the studies. AVXL is taking a huge leap of faith in claiming these studies have positive implications of their drugs when in fact their drugs may not be designed or proven to do what is being claimed. I found 7 such PRs in the last 2 years on their website with the following dates: 5/21/15, 8/19/14, 6/30/14, 5/22/14, 4/29/14, 3/10/14 and 10/22/13.
The Phase 1 study was conducted in Germany, and the current Phase 2a study is being conducted in Australia. In fact I cannot find any reference of AVXL ever speaking with the FDA or applying for an IND to conduct studies in the U.S. They claim regulatory approval for the Phase 2a, but that was just from the Ethics Committee in Australia, not the FDA. They will need FDA approval if they ever want to market this in the US.
I welcome opposing opinions and corrections to my research above. Thanks